BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 6469513)

  • 1. A comparative study of therapeutic activity, myelotoxicity and DNA damage in the bone marrow of mice after cyclophosphamide and ASTA Z 7557 (INN mafosfamide).
    Berger MR; Bedford P; Zeller WJ; Kaufmann M
    Invest New Drugs; 1984; 2(2):181-6. PubMed ID: 6469513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of ASTA Z 7557 (INN mafosfamide) and cyclophosphamide on hematopoiesis in mice.
    Nowrousian MR; Schmidt CG
    Invest New Drugs; 1984; 2(2):207-13. PubMed ID: 6469516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental toxicology of ASTA Z 7557 (INN mafosfamide).
    Pohl J; Hilgard P; Jahn W; Zechel HJ
    Invest New Drugs; 1984; 2(2):201-6. PubMed ID: 6469515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.
    Zeller WJ; Berger MR; Matys R; Schuhmacher J
    Invest New Drugs; 1984; 2(2):175-80. PubMed ID: 6469512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
    Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B
    Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of 4-(2-sulfonatoethylthio)-cyclophosphamide cyclohexylamine salt (ASTA Z 7557, INN mafosfamide) after intraperitoneal administration to mice.
    Roberts JD; Hacker MP; Newman RA; McCormack JJ; Krakoff IH
    Invest New Drugs; 1984; 2(2):215-20. PubMed ID: 6469517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of toxicity and therapeutic efficacy of a stabilized cytostatic metabolite of cyclophosphamide (ASTA Z 7557, INN mafosfamide).
    Klein HO; Wickramanayake PD; Christian E; Coerper C
    Invest New Drugs; 1984; 2(2):191-9. PubMed ID: 6469514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes.
    de Jong JP; Nikkels PG; Brockbank KG; Ploemacher RE; Voerman JS
    Cancer Res; 1985 Sep; 45(9):4001-5. PubMed ID: 3896474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
    Kohn FR; Sladek NE
    Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).
    Slavin S; Mumcuoglu M; Landesberg-Weisz A; Kedar E
    Bone Marrow Transplant; 1989 Sep; 4(5):459-64. PubMed ID: 2676042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101).
    Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B
    Cancer Res; 1993 Apr; 53(8):1838-44. PubMed ID: 8467503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
    Hagenbeek A; Martens AC
    Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preferential differentiation of murine CFU-S toward granulopoiesis and megakaryocytopoiesis after in vitro incubation of bone marrow with ASTA-Z 7557.
    Sainteny F; Lopez M; Mary JY; Frindel E
    Exp Hematol; 1987 Jul; 15(6):631-5. PubMed ID: 3297759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
    Mumcuoglu M; Naparstek E; Slavin S
    Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen.
    Sefc L; Psenák O; Sýkora V; Sulc K; Necas E
    J Hematother Stem Cell Res; 2003 Feb; 12(1):47-61. PubMed ID: 12662436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
    Lopez M; Mary JY; Sainteny F
    Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
    Tamayo E; Hervé P
    Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative activity of 2-[N, N-bis-(2-chloroethyl)-amino]-4-[2-sulfonato-ethylthio]-tetrah ydr o-2H-1 , 3,2-oxazaphosphorine-2-oxide cyclohexamine (ASTA Z 7557, INN mafosfamide) against human and murine tumor cells in vitro.
    Kovach JS; Svingen PA
    Invest New Drugs; 1984; 2(2):155-9. PubMed ID: 6469509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.